NEU neuren pharmaceuticals limited

Acadia, page-1350

  1. 630 Posts.
    lightbulb Created with Sketch. 343
    That's a solid quarter. I think they'll be playing conservative with the guidance for 2025. I don't like getting too caught up in just focusing on Daybue but that's all the market seems to take an interest in for now. They should have close to two months of new sales data for Q1 25 and it will be interesting how much the seasonal effect plays out again. My guess is it's fairly significant. Guiding to a midpoint less than 100 million per quarter which is less than 5% up on your Q4 number suggests Q1 sales will be down again and the rest of the year does the heavy lifting. I suspect it should get a mention in the call. But as I say this should not be given the weight that it may with the potential of 2591 being the main driver of future SP growth.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$13.31
Change
0.770(6.14%)
Mkt cap ! $1.655B
Open High Low Value Volume
$12.96 $14.00 $12.91 $19.76M 1.453M

Buyers (Bids)

No. Vol. Price($)
1 3000 $13.30
 

Sellers (Offers)

Price($) Vol. No.
$13.33 3716 1
View Market Depth
Last trade - 16.10pm 26/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.